Common Stock, par value $0.0001 per share
- Symbol
- VVOS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Vivos Therapeutics, Inc.
VVOSNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 5, 2026, Vivos Therapeutics, Inc. issued a press release announcing the issuance of its new US Patent No. 12,697,190. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Registered securities in this filing
Vivos Therapeutics, Inc. · 8-K · Filed 2026-08-11
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01. Regulation FD Disclosure.
On
August 5, 2026, Vivos Therapeutics, Inc. issued a press release announcing the issuance of its new US Patent No. 12,697,190.
A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The
information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section,
and shall not be deemed incorporated by reference into any filing under the Securities Act, or the Exchange Act, as amended, except as
expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology Continuation Patent Secures Broader, Design Independent Claims, Building on the Company’s 2024 Foundational Patent for Its Vibrational Oral Appliance Platform LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) - Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, today announced that the United States Patent and Trademark Office has issued US Patent No. 12,697,190 “Vibrational Oral Appliance with Mandibular Advancements” (the “‘190 Patent”), a continuation of the Company’s previously issued US Patent No. 12,048,608 (the “‘608 Patent”), issued July 30, 2024. Taken together, these two patents broaden the patent protections around Vivos’ proprietary line of oral medical devices known as Vivos CARE devices. In 2023 and 2024, the FDA granted two separat…
Open exhibit ↗